Komori
Presentation materials for financial results4527ROHTO PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Briefing on Financial Results for the Fiscal Year Ending March 2026 (April 2025 to March 2026)

In the fiscal year ending March 2026, sales increased in all regions, and both revenue and operating profit exceeded the full-year forecasts. Although the cost ratio and SG&A expenses rose, the effects of higher revenue and increased non-operating income led to increases in operating profit, ordinary profit, and net income.

Worth reading
80Important
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
11.4
Year-on-year change in revenue (%)
Wording
Conditional
How definitive the wording is.

Contents of this document

Presentation materials for financial resultsFiscal year ending March 2026, full year13 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥343,725 million+11.4%
Operating profit¥41,118 million+7.5%
Ordinary income¥47,971 million+20.8%
Net income¥34,247 million+11.0%
Gross Profit Margin56.1 %
Operating profit margin12 %
Selling, general and administrative expenses¥151,576 million
Results for the three months of the current quarter
Net Sales
¥90,654 million+9.6%
Operating profit
¥7,543 million+20.2%
Ordinary income
¥8,119 million+22.1%
Net income
¥5,968 million-2.1%
Full-year earnings forecast
Net Sales
¥369,500 million
Operating profit
¥43,800 million
Ordinary income
¥46,100 million
Net income
¥34,500 million
EBITDA
¥62,552 million
Earnings per share
¥152.68
Progress against full-year forecast　通期の予想に対して、いまどこまで進んだかの割合です。
Segment revenue
Japan99.8
Asia102.6
Americas101.7
Europe99.5
Other103.7
Overseas total102
Total100.9
Segment operating profit
Japan98.3
Asia106
Americas106.6
Europe91.6
Other127.9
Adjustments105.8
Total101.5
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Revenue and operating profit both exceeded the published forecasts. Japan was broadly in line with the plan, while Asia and the Americas finished above plan. Operating profit in Europe fell short of plan.
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
  • Higher sales from the consolidation of EYS and モノ社, and higher sales at Rohto on a standalone basis and in Southeast Asia¥19,833 million
  • Cost of sales¥-1,531 million
  • Promotional expenses¥-3,377 million
  • Advertising spend¥-1,717 million
  • Research and development costs¥1,185 million
  • Personnel expenses¥-4,029 million
  • Other¥-7,478 million
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
Foreign exchange
Dollar-yen155
Yuan/yen22
Higher crude oil prices and other factorsAlready incorporated to the extent currently identifiable
New initiatives
  • Submission of an application for approval of ROH101
  • Contract manufacturing of iPS cell-derived corneal epithelial cell sheets for レイメイ
  • Contract manufacturing of clinical trial products for ヒューマンライフコード
  • Launch in China of a wearable medical device for overactive bladder treatment
  • Entry into the Thai and Serbian markets
  • Share repurchases of up to ¥3 billion scheduled for 2026
Key KPIsA metric the company considers important as a management benchmark.
  • EBITDA¥58,496 million
    Year on year against the same period last year+13.5%
  • EBITDA margin17 %
    Year on year against the same period last year+0.3%
  • ROE12.1 %
    Year on year against the same period last year0.0%
  • Inbound DemandRecord high
Segment results
Net Sales
Japan
¥169,326 million+2.6%
Asia
¥125,327 million+24.9%
Americas
¥21,553 million+3.8%
Europe
¥23,889 million+24.7%
Other
¥3,628 million+7.8%
Operating profit
Japan
¥22,126 million-1.5%
Asia
¥15,048 million+29.8%
Americas
¥1,705 million+10.6%
Europe
¥1,007 million-28.8%
Other
¥383 million+8.3%
Medium-term management plan targets
Target fiscal yearFY2030
Net Sales4,150
Revenue unitHundreds of millions of yen
Operating profit540
Operating profit unitHundreds of millions of yen
Operating profit margin13
Comparison with actual resultsExpected to reach the fiscal 2027 revenue forecast one year ahead of schedule
Financial targets
Actual ROE12.1
ROE unit%
Market Size / Share
Countries where Hada Labo is sold60 countries and regions
Global eye-drop unit salesNo.1
Trademark registrations118 countries and regions
Capital expenditures
¥21,800 million
Annual Dividend
Annual dividend per share¥50
Interim¥25
End of period¥25
Payout ratio
32.7
Acquisition of treasury shares
30 Hundreds of millions of yen
Period2026 forecast
Contents of this document
ItemDetails
Document typePresentation materials for financial results
Fiscal Period CoveredFiscal year ending March 2026, full year
Net Sales¥343,725 million (YoY +11.4%)
Operating profit¥41,118 million (YoY +7.5%)
Ordinary income¥47,971 million (YoY +20.8%)
Net income¥34,247 million (YoY +11.0%)
Gross Profit Margin56.1 %
Operating profit margin12 %
Selling, general and administrative expenses¥151,576 million
Results for the three months of the current quarterNet Sales ¥90,654 million (YoY +9.6%) / Operating profit ¥7,543 million (YoY +20.2%) / Ordinary income ¥8,119 million (YoY +22.1%) / Net income ¥5,968 million (YoY -2.1%)
Full-year earnings forecastNet Sales ¥369,500 million / Operating profit ¥43,800 million / Ordinary income ¥46,100 million / Net income ¥34,500 million / EBITDA ¥62,552 million / Earnings per share ¥152.68
Progress against full-year forecastConsolidated revenue Not disclosed / Consolidated operating profit Not disclosed / Segment revenue Japan 99.8 / Asia 102.6 / Americas 101.7 / Europe 99.5 / Other 103.7 / Overseas total 102 / Total 100.9 / Segment operating profit Japan 98.3 / Asia 106 / Americas 106.6 / Europe 91.6 / Other 127.9 / Adjustments 105.8 / Total 101.5
Self-assessment against the planRevenue and operating profit both exceeded the published forecasts. Japan was broadly in line with the plan, while Asia and the Americas finished above plan. Operating profit in Europe fell short of plan.
Segment resultsNet Sales Japan ¥169,326 million (YoY +2.6%) / Asia ¥125,327 million (YoY +24.9%) / Americas ¥21,553 million (YoY +3.8%) / Europe ¥23,889 million (YoY +24.7%) / Other ¥3,628 million (YoY +7.8%) / Operating profit Japan ¥22,126 million (YoY -1.5%) / Asia ¥15,048 million (YoY +29.8%) / Americas ¥1,705 million (YoY +10.6%) / Europe ¥1,007 million (YoY -28.8%) / Other ¥383 million (YoY +8.3%)
Breakdown of Factors Affecting the ChangeFactors Higher sales from the consolidation of EYS and モノ社, and higher sales at Rohto on a standalone basis and in Southeast Asia / Amount ¥19,833 million, Factors Cost of sales / Amount ¥-1,531 million, Factors Promotional expenses / Amount ¥-3,377 million, Factors Advertising spend / Amount ¥-1,717 million, Factors Research and development costs / Amount ¥1,185 million, Factors Personnel expenses / Amount ¥-4,029 million, Factors Other / Amount ¥-7,478 million
Key KPIsIndicator name EBITDA / Value ¥58,496 million / Year on year against the same period last year ¥13.5 million, Indicator name EBITDA margin / Value 17 % / Year on year against the same period last year 0.3 %, Indicator name ROE / Value 12.1 % / Year on year against the same period last year 0 %, Indicator name Inbound Demand / Value Record high / Year on year against the same period last year Not disclosed
Assumptions Underlying the Business OutlookForeign exchange Dollar-yen 155 / Yuan/yen 22 / Higher crude oil prices and other factors Already incorporated to the extent currently identifiable
Medium-term management plan targetsTarget fiscal year FY2030 / Net Sales 4,150 / Revenue unit Hundreds of millions of yen / Operating profit 540 / Operating profit unit Hundreds of millions of yen / Operating profit margin 13 / Comparison with actual results Expected to reach the fiscal 2027 revenue forecast one year ahead of schedule
Financial targetsActual ROE 12.1 / ROE unit %
Annual DividendAnnual dividend per share ¥50 / Interim ¥25 / End of period ¥25
Payout ratio32.7
Acquisition of treasury sharesAmount 30 Hundreds of millions of yen / Period 2026 forecast
Capital expenditures¥21,800 million
Market Size / ShareCountries where Hada Labo is sold 60 countries and regions / Global eye-drop unit sales No.1 / Trademark registrations 118 countries and regions
New initiativesSubmission of an application for approval of ROH101, Contract manufacturing of iPS cell-derived corneal epithelial cell sheets for レイメイ, Contract manufacturing of clinical trial products for ヒューマンライフコード, Launch in China of a wearable medical device for overactive bladder treatment, Entry into the Thai and Serbian markets, Share repurchases of up to ¥3 billion scheduled for 2026
Items this document does not state (6)
Unit price and quantity metricsNumber of stores and locationsNumber of employeesRisk amount incorporated into the outlookOrders received and order backlogKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The primary factors were higher revenue in all regions, particularly growth in Asia and Europe, the consolidation effects of EYS and モノ社, and the benefits of higher revenue. The cost ratio rose by 0.4 percentage points, while SG&A expenses increased due to amortization and personnel expenses associated with the acquisitions of EYS and モノ社. Non-operating income increased due to dividend income received.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Briefing on Financial Results for the Fiscal Year Ending March 2026 (April 2025 to March 2026) | ROHTO PHARMACEUTICAL CO.,LTD. (4527) timely disclosure | Komori